Neuropsychiatric Toxicity of Phenytoin

Winter ME , Tozer TN Phenytoin. In: Evans WE , Schentag JJ , Jusko WJ , eds. Applied Pharmacokinetics, Principles of Therapeutic Drug Monitoring . 2nd ed. Spokane, WA: Applied Therapeutics; 1986:493-539. 1

Perucca E. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring. Ther Drug Monitor. 1980;2:331-344.

Reidenberg MM , Drayer DE Alteration of drug-protein binding in renal disease. 1 Clin Pharmacokinet. 1984 ;9 (suppl 1):18-26.

Kilpatrick CJ , Wanwimolruk S. , Wing MH Plasma concentrations of unbound phenytoin in the management of epilepsy. 1 Br J Clin Pharmacol. 1984;17:539-546.

MacKichan JJ Pharmacokinetic consequences of drug displacement from blood and tissue proteins. Clin Pharmacokinet. 1984;9 (suppl 1):32-41.

Sjoholm I. , Kober A. , Odar-Cedelof I. , et al. Protein binding in uremia and normal serum: the role of endogenous binding inhibitors. Biochem Pharmacol. 1976 ;25:1205-1213.

Reidenberg MM , Odar-Cederlof I. , Von Bohr C. Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. N Engl J Med. 1971;285:264-267.

Liponi DL , Winter ME , Tozer TN Renal function and therapeutic concentrations of phenytoin. Neurology. 1984;34:395-397.

Gugler R. , Azarnoff DL , Shoeman DW Diphenylhydantoin: correlation between protein binding and albumin concentration . Klin Wochenschr. 1975;53:445-446.

Sheiner LB , Tozer TN Clinical pharmacokinetics: the use of plasma concentrations of drugs . In: Melmon KL , Morrelli HF , eds. Clinical Pharmacology: Basic Principles in Therapeutics. New York, NY: MacMillan; 1978:71-109.

Beck DE , Farringer JA , Ravis WR , Robinson CA Accuracy of three methods for predicting concentrations of free phenytoin . Clin Pharm. 1987;6:888-894.

Stewart CF , Stang C. , Crom WR , et al. Free phenytoin concentrations in pediatric patients. Drug Intell Clin Pharm. 1980;17:448.